Medical Innovation Exchange

JPM, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing, and more

Here we are back again at…our desks; with an abrupt cancellation of the J.P. Morgan Healthcare Conference 2022 coming last month, it’s a second year of being virtual (though that hasn’t stopped some airlines and hoteliers trying to hold on to your cash).

The last few years we’ve seen some mid-size buyout deals coming pre JPM over the weekend, though this time around things are a little more quiet.

But who knows what the next few days will bring. With the likes of Pfizer and Moderna expecting to make collectively around $50 billion this financial year thanks to their two COVID-19 shots, and up to $100 billion in 2022, there’s fire power out there for some major deals.

Here’s your need to know, from Bayer penning a big biobucks pact with Mammoth as it delves deeper into gene-editing to Pfizer’s similar move with Beam.

Want more? Catch the latest news from Fierce Biotech and Fierce Pharma. And check out tomorrow’s Day 2 roundup covering the on-the-ground skinny from Tuesday’s action.


Monday 6:50 a.m. ET

And here’s another and another from Pfizer. Destined to be an mRNA powerhouse, the Big Pharma locks down two partners to bulk up its tech, including one small biotech that provided a delivery system for the COVID-19 shot. Story


Monday 6 a.m. ET

Company of the moment Pfizer, thanks to its BioNTech-partnered COVID mRNA vaccines, has some observers hoping their favorite biotech may well be in the crosshairs of the newly-minted company.

There’s still plenty of time left, but the early deal out of the New York Big Pharma isn’t a major M&A deal, but rather sees it taking a bigger bite out of the gene editing apple with $300 million upfront in a research collaboration with Beam Therapeutics focused on the biotech’s base editing technique. Story.

Monday 5 a.m. ET

Novartis has like many pharma seen setbacks in helping COVID patients sick with the disease, but today new, positive data out from partner Molecular Partners for its drug hopeful ensovibep has prompted the Swiss pharma to pay CHF 150 million ($163 million) for an asset that could soon add to the anti-omicron arsenal. Story

Monday 3 a.m. ET

German Pharma Bayer was the company to kickstart J.P. Morgan’s healthcare conference 2022, doubling down on its cutting-edge life sciences aspirations buy tapping CRISPR science from Doudna’s lab in $1 billion biobucks Mammoth gene therapy deal.

The collab involves five preselected indications with an initial focus on liver diseases. Story

Ben Adams


Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.